Effects of cyclosporine ophthalmic: A Synthesis of Findings from 19 Studies

  1. Home
  2. Effects of cyclosporine ophthalmic
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of cyclosporine ophthalmic: A Synthesis of Findings from 19 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of cyclosporine ophthalmic: A Synthesis of Findings from 19 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Main Research Findings

Cyclosporine ophthalmic emulsion is a medication used to treat dry eye disease, a condition characterized by insufficient tear production and inflammation of the ocular surface. Studies have shown that cyclosporine ophthalmic emulsion can improve tear production, reduce inflammation, and enhance visual performance in patients with dry eye. 13 10 3 Specifically, research has indicated that cyclosporine ophthalmic emulsion can alleviate common dry eye symptoms such as dryness, irritation, and blurry vision. 9 2 Additionally, the medication has shown promise in improving the function of meibomian glands, which are responsible for producing a type of oil that contributes to tear film stability. 1 It has also been found to be effective in preventing dry eye after certain types of eye surgery, such as trabeculectomy. 6 8

Benefits and Risks

Benefits Summary

Cyclosporine ophthalmic emulsion offers several potential benefits for patients with dry eye, including increased tear production, reduced inflammation, improved visual performance, and better meibomian gland function.

Risks Summary

While generally well-tolerated, cyclosporine ophthalmic emulsion can cause side effects such as eye irritation, redness, and blurry vision. The long-term effects of this medication are still being studied.

Comparison of Studies

Commonalities Among Studies

A consistent finding across numerous studies is the effectiveness of cyclosporine ophthalmic emulsion in improving dry eye symptoms. Several studies demonstrate its ability to reduce inflammation on the ocular surface.

Differences Among Studies

The effectiveness of cyclosporine ophthalmic emulsion may vary depending on the concentration and formulation used. 10 Additionally, the severity and type of dry eye may influence the medication’s efficacy and potential side effects. 12 3

Consistency and Contradictions in Results

While many studies support the effectiveness of cyclosporine ophthalmic emulsion for dry eye, it’s important to recognize that individual responses to the medication can vary. Factors such as the patient’s underlying condition and the specific formulation used may influence the observed outcomes.

Implications for Everyday Life

Cyclosporine ophthalmic emulsion can be a valuable treatment option for managing dry eye symptoms. However, it’s crucial to be aware of potential side effects and to discuss the medication’s use with an eye care professional. Regular eye exams are recommended to monitor progress and identify any adverse reactions.

Limitations of Current Research

Further investigation is needed to fully understand the long-term effects of cyclosporine ophthalmic emulsion. Additional research is also necessary to determine how the medication’s effectiveness varies depending on the type and severity of dry eye.

Future Research Directions

Future research should focus on clarifying the long-term impact of cyclosporine ophthalmic emulsion and exploring how its effectiveness varies based on the specific type and severity of dry eye. Developing new formulations of cyclosporine ophthalmic emulsion with improved efficacy and safety profiles is also a key area for future research.

Conclusion

Cyclosporine ophthalmic emulsion shows promise as a treatment for dry eye disease, demonstrating its ability to improve tear production, reduce inflammation, and enhance visual performance. However, it is essential to be aware of potential side effects and to consult with an eye care professional for personalized advice and monitoring. Continued research is needed to optimize the use of cyclosporine ophthalmic emulsion and develop even better treatment options for dry eye.

Literature analysis of 19 papers
Positive Content
17
Neutral Content
0
Negative Content
2
Article Type
7
1
1
4
18
1.

A randomized double-masked study of 0.05% cyclosporine ophthalmic emulsion in the treatment of meibomian gland dysfunction.

Author: PrabhasawatPinnita, TesavibulNattaporn, MahawongWannaree

MGD treatment

Topical cyclosporine 0.05% twice daily may be helpful in the treatment of meibomian gland dysfunction by improving tear film stability.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

2.

Efficacy, Safety, and Tolerability of a Novel Cyclosporine, a Formulation for Dry Eye Disease: A Multicenter Phase II Clinical Study.

Author: PengWen-Yan, ChenRong-Xin, DaiHong, ZhuLei, LiYing, GaoZi-Qing, LiXiao-Yi, ZhouShi-You

Comfort profile
DED improvement
Safety & tolerability
Ocular-related AEs

This Phase II clinical trial investigated the efficacy, safety, and tolerability of a novel cyclosporine formulation (CyclAGel) for dry eye disease (DED). CyclAGel showed consistent improvement in eye dryness score, symptoms of dryness, corneal fluorescein staining, breakup time, and Schirmer test scores compared to Restasis. While CyclAGel showed promising results, no statistically significant differences were found between CyclAGel and Restasis after baseline corrections. Further research with longer follow-up is needed to confirm these findings.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

3.

Efficacy and safety of 0.05% cyclosporine ophthalmic emulsion in treatment of Chinese patients with moderate to severe dry eye disease: A 12-week, multicenter, randomized, double-masked, placebo-controlled phase III clinical study.

Author: ChenDi, ZhangShunhua, BianAiling, HongJing, DengYingping, ZhangMingchang, ChenWei, ShaoYan, ZhaoJialiang

DED treatment

This study aims to compare the efficacy and safety profile of 0.05% cyclosporine ophthalmic emulsion (CsA OE) versus vehicle in Chinese patients with moderate to severe dry eye disease (DED). CsA OE is a long-standing treatment for DED in the US, but is not commercially available in China.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

4.

Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial.

Author: LiewShiao Hui Melissa, NicholsKelly K, KlamerusKaren J, LiJim Z, ZhangMin, FoulksGary N

Dry eye treatment
Not statistically significant

This phase 1/2 study of tofacitinib demonstrated a trend for improving both signs and symptoms of dry eye. All doses of tofacitinib exhibited a reasonable safety profile and were well tolerated by patients with DED.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

6.

Effects of postoperative cyclosporine ophthalmic emulsion 0.05% (Restasis) following glaucoma surgery.

Author: FakhraieGhasem, LopesJoao F, SpaethGeorge L, AlmodinJuliana, IchhpujaniParul, MosterMarlene R

Improved ocular surface symptoms
None mentioned

Topical cyclosporine 0.05% had no effect on postoperative bleb function and intraocular pressure following trabeculectomy, but improved subjective ocular surface symptoms in these patients.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

7.

Treatment of keratoconjunctivitis sicca in dogs with cyclosporine ophthalmic ointment: a European clinical field trial.

Author: SansomJ, BarnettK C, NeumannW, Schulte-NeumannA, ClercB, JegouJ P, de HaasV, WeingartenA

Conjunctival health improvement
Lacrimal secretion increase
Mild irritation

Cyclosporine ophthalmic ointment (0.2%) was effective in treating chronic idiopathic keratoconjunctivitis sicca in dogs. Lacrimal secretion increased significantly, and conjunctival health improved in most dogs. Only mild irritation was observed.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Language : English

8.

Dry eye symptoms following cataract surgery.

Author: RobertsCalvin W, ElieEleanor R

Dry eye symptom reduction
Improved vision

This randomized, controlled clinical study investigated the development of dry eye-type symptoms after cataract extraction and the effectiveness of topical cyclosporine ophthalmic emulsion in reducing these symptoms. The study found that topical cyclosporine was effective in reducing the occurrence of dry eye-type symptoms after cataract surgery, suggesting that cyclosporine should be considered for patients with dry eyes or at risk of developing dry eye.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

9.

Efficacy and Safety of a Water-Free Topical Cyclosporine, 0.1%, Solution for the Treatment of Moderate to Severe Dry Eye Disease: The ESSENCE-2 Randomized Clinical Trial.

Author: AkpekEsen K, WirtaDavid L, DowningJohnathon E, TauberJoseph, SheppardJohn D, CiolinoJoseph B, MeidesAlice S, KrösserSonja

Dry eye treatment
Ocular surface

This study found that a water-free cyclosporine ophthalmic solution, 0.1%, resulted in early therapeutic effects on the ocular surface compared with vehicle in patients with dry eye disease (DED).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

10.

Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.

Author: SallK, StevensonO D, MundorfT K, ReisB L

Improved Schirmer values
Improved blurred vision
Improved corneal staining

CsA 0.05% and 0.1% ophthalmic emulsions were safe and effective in treating moderate to severe dry eye disease.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

11.

Product Quality Research for Developing and Assessing Regulatory Submissions for Generic Cyclosporine Ophthalmic Emulsions.

Author: BelenosAvery, WoodErin Leigh, HuMeng, KozakDarby, XuXiaoming, FisherAdam C

Improved availability
Increased tear production

This article describes the approval of the first generic cyclosporine ophthalmic emulsion (COE) in the US. This achievement involved overcoming scientific challenges to determine therapeutic equivalence to the original drug.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Language : English

12.

Cyclosporine 0.05% ophthalmic emulsion for dry eye in Korea: a prospective, multicenter, open-label, surveillance study.

Author: ByunYong-Soo, RhoChang Rae, ChoKyungjin, ChoiJin A, NaKyung Sun, JooChoun-Ki

Improved dry eye symptoms
Reduced artificial tear use
Reduced conjunctival staining
Ocular pain

Cyclosporine ophthalmic emulsion 0.05% was found to be an effective and tolerable treatment for dry eye disease in Korean patients. The treatment significantly reduced ocular symptoms and improved Schirmer scores, while also reducing conjunctival staining and the use of artificial tears.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

14.

Physician Satisfaction with Anti-Inflammatory Topical Medications for the Treatment of Dry Eye Disease.

Author: WhiteDarrell E, ZhaoYang, JayapalanHemalatha, MachirajuPattabhi, PeriyasamyRamu, OgundeleAbayomi

Dry eye disease treatment

This survey-based study assessed physician satisfaction with cyclosporine ophthalmic emulsion 0.05% (CYC) and lifitegrast 5% ophthalmic solution (LIF) for the treatment of dry eye disease (DED).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

15.

Ocular graft-versus-host disease.

Author: HessenMichelle, AkpekEsen K

Effective treatment
Vision saving

Ocular involvement is common in patients with graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation. Dry eye is the most frequent finding, but posterior segment complications are also not infrequent. Treatment with T-cell suppressants is often effective.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

16.

Incidence of new coding for dry eye and ocular infection in open-angle glaucoma and ocular hypertension patients treated with prostaglandin analogs: retrospective analysis of three medical/pharmacy claims databases.

Author: SchwartzGail F, KotakSameer, MardekianJack, FainJoel M

Treat glaucoma
Dry eye
Ocular infection

This study compared the incidence of dry eye, ocular infection, or ocular surface disease in patients newly treated with latanoprost with benzalkonium chloride (BAK) or travoprost-Z with SofZia®. The study found no significant difference in incidence rates between the two formulations after one year.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

17.

Interventions for rosacea.

Author: van ZuurenEsther J, KramerSharon, CarterBen, GraberMark A, FedorowiczZbys

Rosacea treatment

Rosacea, a common skin condition affecting the face, causes redness, pimples, and dilated blood vessels. While several treatments exist, the most effective options remain unclear.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

18.

Transient light sensitivity after femtosecond laser flap creation: clinical findings and management.

Author: StonecipherKarl G, DishlerJon G, IgnacioTeresa S, BinderPerry S

Photosensitivity

Photosensitivity after LASIK with femtosecond flap creation may be related to the pulse energy used for flap creation. Lowering raster and side-cut energy settings can significantly reduce the incidence of this complication. Prompt steroid therapy can improve symptoms, which typically resolve within a week.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

19.

Limbitis secondary to autologous serum eye drops in a patient with atopic keratoconjunctivitis.

Author: WelderJeffrey David, BakhtiariPejman, DjalilianAli R

Limbitis

This case report describes a patient with atopic keratoconjunctivitis (AKC), a condition characterized by dry eyes and inflammation of the eyelids and conjunctiva, who developed limbitis, inflammation of the edge of the eyelid, after starting autologous serum eye drops (ASEDs). Limbitis resolved after stopping ASEDs, highlighting the potential for ASEDs to cause side effects.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.